Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title Hits
12 Mar 2010 Ipsen Grants Rhythm Exclusive Worldwide License 12
11 Mar 2010 Allon's Phase 1 Trial Broadens Davunetide's Intranasal Safety and Dose Range 35
11 Mar 2010 FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 28
11 Mar 2010 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 21
11 Mar 2010 ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer 22
10 Mar 2010 BOTOX (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults 42
09 Mar 2010 BioMimetic Therapeutics Presents Promising Pre-Clinical Sports Medicine Data at the 2010 ORS Meeting 45
08 Mar 2010 Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research Society 93
04 Mar 2010 Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer 67
03 Mar 2010 Novo Nordisk receives FDA approval for Norditropin FlexPro for growth hormone treatment (3 March 2010) 94
02 Mar 2010 Zealand Pharma and PolyTherics enter Collaboration Agreement for novel optimised biopharmaceuticals 65
02 Mar 2010 Capstone Therapeutics Announces Continuation of AZX100 Phase 2 Clinical Trial in Keloid Scarring 49
01 Mar 2010 FDA Accepts VIAject(R) NDA for Review 79
26 Feb 2010 Agennix AG Announces Longer-Term Mortality Results From Talactoferrin Phase 2 Trial in Severe Sepsis 69
26 Feb 2010 Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 75
25 Feb 2010 Data from a post hoc analysis using desmoteplase in ischaemic stroke presented at the International Stroke Conference 76
25 Feb 2010 Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety 115
24 Feb 2010 Lorus Announces Publication Demonstrating Antitumor Efficacy of Interleukin 17E 59
24 Feb 2010 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) 62
24 Feb 2010 Pantec Biosolutions reports successful Phase I for delivery of FSH using P.L.E.A.S.E.® 97
23 Feb 2010 Allon Presents Peripheral Neuropathy Preclinical Efficacy Data For AL-309 60
22 Feb 2010 EnzymeRx Provides a Clinical Update on Pegsitacase 69
22 Feb 2010 Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity 76
19 Feb 2010 Polyphor Discovers a New Class of Antibiotics with a Novel Mode of Action 69
18 Feb 2010 HEMATIDE™ ENTERED INTO THE PHASE 3 CLINICAL PROGRAM TO TREAT ANEMIA IN CHRONIC RENAL FAILURE PATIENTS IN JAPAN 102
18 Feb 2010 Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement 89
17 Feb 2010 Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics 94
17 Feb 2010 Marcadia Initiates Phase 1 Clinical Trial of GLP-1/GIP Dual Agonist MAR701 93
17 Feb 2010 Pharming’s C1 Inhibitor Product Potentially Effective In Reducing Complications Following Transplantation 73
16 Feb 2010 Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit in Preventing Influenza-Like Illness in Older Participants 76
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 2042

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics